Background: The objective of this study was to analyse the relationship of polymorphisms of the angiotensinogen (AGT) gene with the changes in microalbuminuria during 3 years of antihypertensive treatment in a group of young adults with essential hypertension. Methods: Essential hypertensives, less than 50 years old, never previously treated with antihypertensive drugs and in the absence of diabetes mellitus were included. After the initial evaluation, patients were treated using only nonpharmacological measures (n ¼ 23), only b-blockers (n ¼ 26), only angiotensin-converting enzyme inhibitors (ACEi) (n ¼ 57) or a combination of treatments (n ¼ 25). The office blood pressure, biochemical profile and urinary albumin excretion (UAE) were measured at the beginning and then yearly. The polymorphism A-6G of the AGT gene located in the promoter region was analysed. Results: In total, 131 patients, 35 (27%) microalbuminurics, were included. Although no significant differences in systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose and UAE were observed among genotypes at the initial examination, during the 3 years of antihypertensive treatment the slope values for the DBP, fasting glucose and UAE differed significantly despite no differences in the distribution of treatments being present. The subjects carrying the AA-6 genotype had the largest DBP decrease, but the lowest UAE reduction and the highest slope of glucose. Out of 35 initially microalbuminuric patients, 24 became normoalbuminuric and the lowest reduction rates were observed in subjects who carried the allele A-6. No interaction between the type of treatment and genotype was observed on the changes in UAE, BP or glucose values. In the subset of 57 patients treated with ACEi, the changes in UAE, BP and glucose had the same trend as was observed in the total population. Conclusions: Subjects carrying the AA genotype of the A-6G AGT gene polymorphism are resistant to a reduction of microalbuminuria. Whether this can be attributed to a predisposition to glucose metabolic disturbance or not needs to be confirmed in further studies.
Introduction
Microalbuminuria has become an early marker of organ damage in hypertension, and preliminary data supporting microalbuminuria as a prognostic marker for cardiovascular and/or renal risk in hypertension have recently been reported. 1, 2 Previous studies from our group and others, using transversal studies, have demonstrated that in essential hypertension, microalbuminuria is related to the levels of blood pressure (BP) values 3, 4 and to the presence of hyperinsulinaemia 5, 6 as an expression of insulin resistance. 5 The BP values and insulin resistance, however, only partly explain the presence or absence of microalbuminuria in hypertensives. The genetic background, among other factors, could contribute to the development of microalbuminuria in hypertension. 7, 8 The molecular variants of the angiotensinogen (AGT) gene, a key component of the renninangiotensin system (RAS), are considered genetic risk factors for primary hypertension. 9 Polymorphisms of the coding and the promoter regions, M235T and A-6G, respectively, have been linked to the AGT plasma levels and to the risk of hypertension in several studies, [10] [11] [12] [13] [14] but not in others. 15, 16 Crosssectional association studies, meanwhile, have reported a lack of impact of the polymorphisms of the AGT gene on microalbuminuria. [17] [18] [19] Observing the changes in microalbuminuria during antihypertensive treatment in patients carrying different alleles of the polymorphisms is another potential approach to studying whether or not polymorphisms of the AGT gene influence microalbuminuria. In the present study, the influence of the A-6G polymorphisms of the AGT gene on the outcome of microalbuminuria during a 3-year antihypertensive treatment was analysed in a group of young adults with essential hypertension, never previously treated with antihypertensive drugs. The particular response of microalbuminuria in patients receiving angiotensin-converting enzyme inhibitors (ACEi) was also analysed.
Material and methods

Selection of study participants
Patients included in the study were selected from an outpatient clinic over a 5-year period (January 1990-December 1994). All patients who fulfilled the inclusion criteria were invited to participate and written consent was requested. The inclusion criteria were the following: (a) diastolic blood pressure (DBP) ranging from high normal to moderate essential hypertension, defined as being between 85 and 114 mmHg (Korotkoff phase V, sitting position) for three visits at 1-month intervals; (b) from 25 to 50 years of age (c) the absence of cardiovascular events; (d) glomerular filtration rate greater than 60 ml/min/1.73m 2 ; (e) never previously treated for hypertension. Patients with nephropathy, diabetes mellitus, urinary tract infection, fasting glucose in serum 4120 mg/dl or with a positive dipstick for albumin or glucose were excluded. In total, 140 patients, all of them Caucasians, were included.
Clinical and analytical procedures
BP was measured in a quiet environment using a mercury sphygmomanometer with the patient in a sitting position after 5 min of rest, following the recommendations of the British Hypertension Society. The systolic blood pressure (SBP) and DBP were measured according to Korotkoff phases I and V, respectively.
The blood samples were obtained in the morning, after fasting for a minimum of 8 h. The serum biochemical profiles and lipids were measured. The glomerular filtration rate (GFR) was estimated by the clearance of endogenous creatinine as expressed in reference to body surface (ml/min/ 1.73 m 2 ).
Urinary albumin excretion for two separate 24-h urine collections was measured using an immunonephelometric assay (Boehring Institute, Mannheim, Germany). Aliquots of urine were taken over the 24-h period, stored in glass tubes at 41C, and analysed 1-7 days after collection. For each patient, the UAE was considered as the mean of values obtained in the two separate 24-h urine collections. If a difference of values obtained between the two samples was greater than 25% of the higher value or a creatinine excretion over 24 h was lower than expected for body size and sex, a third sample was requested. On the basis of UAE, hypertensive patients were classified as normoalbuminuric (UAEo30 mg/24 h) and microalbuminuric (UAE 30-300 mg/24 h) in the two urine collections.
After inclusion, and according to clinical criteria other than microalbuminuria, patients were placed in a nonpharmacological treatment, moderate salt restriction and low calorie diet if overweight was present, with or without a regimen of antihypertensive drugs based on b-blockers (bB) or ACEi. Hydroclorothiazide was added when necessary to maintain the BP goal of o135/85 mmHg. From the initial 140 patients, 131 completed the 3-year study. In all, 23 patients received only nonpharmacological treatment, 26 bB, 57 ACEi and the remaining 25 received several treatments over time for various reasons. During the 3-year follow-up, UAE, renal function and other parameters were assessed yearly.
Polymorphisms of the AGT gene
We have tested the polymorphism A-6G located in the promoter region, and the polymorphism M235T located in exon 2 of the AGT gene. We amplified the 3 0 -promoter region and exon 1 with oligonucleotides 5 0 -GAG GTC CCA GCG TGA GTG TCG C and 5 0 -CTC AGT TAC ATC CTG AGA GAG ACA AGA CC, and exon 2 with oligonucleotides 5 0 -ATA GCC AGG CCC AGA TGC TGC and 5 0 -TGG ATA CTA AGT CCT AGG GCC AGA GC, all under standard PCR conditions. The fragments were analysed with SSCP using water-cooled vertical minigels (10 Â 10 cm). After adding 9 ml of loading buffer to 1 ml of PCR product, the mix was denatured and was loaded into the 1 ml gel. The electrophoresis conditions were the following: 14% acrylamide (29:1 acrylamide:bisacrylamide) into 1 Â TBE buffer at 400 V for 3 h at 151C. After this, the gels were silver stained. The SSCP bands were assigned by direct PCR sequencing of several individuals in both the cases.
There was a nearly complete linkage disequilibrium between the A-6G polymorphism in the promoter region with the M235T polymorphism in exon 2. In the present data, about 95% of the A-6 alleles have a T allele at 235, and about 96% of G-6 alleles have an M allele at the same position. These data were in agreement with the results of other authors.
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Statistical analysis
For each variable, the values were expressed as means and as 95% confidence intervals. Data on UAE were analysed in two ways. First, the data were categorized into normoalbuminuric and microalbuminuric groups, as previously defined, and second, as a continuous variable with logarithmic transformation (logUAE). The variables used in the statistical analysis were the values of the BP, UAE and biochemical profile at the time of starting the study. The changes of parameters during the follow-up were estimated as the individual specific regression line slope values constructed from four points, baseline and yearly values. One-way analysis of variance, Kruskal-Wallis and Fisher's tests were used to compare the parameters between patients with and without microalbuminuria, and among patients with different genotypes. Multiple regression analysis was performed to assess the factors related to the changes in UAE during the follow-up and related to the interaction of genotypes. The association between polymorphisms and UAE was examined using a codominant inheritance model of the alleles.
Results
General characteristics of the study population
The general characteristics, BP values, renal function and UAE in the hypertensives who completed the study are shown in Table 1 . At the beginning, 96 (73%) of the patients were normoalbuminuric, while 35 (27%) were microalbuminuric. The microalbuminuric group had significantly higher BP values than did the normoalbuminuric ones.
The genotype distribution and allele frequencies of both polymorphisms in the normoalbuminurics and the microalbuminurics at baseline are shown in Table 2 . No differences in the presence of microalbuminuria were observed among the genotypes of the A-6G AGT gene polymorphism. The allele frequency of the A-6G polymorphism were not significantly different between normoalbuminurics and microalbuminurics.
Genotypes of the A-6G AGT polymorphism, BP and urinary albumin excretion in the total population
The values of SBP, DBP, fasting glucose and UAE at the beginning and after the 3 years of follow-up and Angiotensinogen gene and outcome of microalbuminuria P Marin et al their slopes in the genotypes of the A-6G polymorphism are shown in Table 3 . Among A-6G polymorphism genotypes, no significant differences in SBP, DBP, fasting glucose and UAE was observed at the initial examination. During the follow-up, a significant reduction in SBP, DBP and UAE was found, but in contrast, the fasting glucose values increased significantly (Table 3) . Of the 108 patients who were treated with antihypertensive drugs, 57 of them received ACEi-based treatment. Patients treated with ACEi had a significantly higher UAE reduction than did those treated with non-ACEi (UAE slopes of À3.80 and À0.74, respectively; Po0.05), although no differences in the SBP, DBP, fasting glucose and UAE values were present between both the groups of treatment at the beginning.
The slope values for the DBP, fasting glucose and UAE differed significantly among genotypes (Table  3) , despite no differences in the distribution of treatments being present (subjects receiving ACEi were 14 out of 31 in the AA, 25 out of 63 in the AG and 17 out of 37 in the GG genotypes). Subjects carrying the AA-6 genotype had the largest DBP decrease, but the lowest UAE reduction (Figure 1) . The slope for glucose was also significantly higher in subjects with the A-6 allele. The same trend of a lower decrease in UAE among those carrying the AA-6 genotype was observed both in patients treated with ACEi (UAE slopes of 0.51, À2.64 and À3.79 for AA, AG and GG genotypes, respectively) as well as in those without ACEi treatment (UAE slopes of 4.65, À2.82 and À0.69 for AA, AG and GG genotypes, respectively).
Genotypes of the A-6G AGT polymorphism, BP and urinary albumin excretion in the microalbuminurics
In the 35 patients who were microalbuminuric at the beginning of the study, significant reductions in SBP (155.5 7 19.9 and 136.4 7 14.3 mmHg, Po0.001), DBP (99.0 7 9.6 and 82.9 7 8.8 mmHg, Po0.001), UAE (69.4 7 48.6/24h and 30.5 7 32.6 mg/24h, Po0.001) and a slight increase in the fasting glucose (104.5 7 12.1 and 107.7 7 14.4 mg/dl, Po0.09) were found. The distribution of treatments did not differ from that used with the subjects in the antihypertensive treatment (19 ACEi and 14 non-ACEi). Subjects treated with ACEi had a slightly greater decrease in UAE than the one observed in the nonACEi group (slope of UAE À10.6 and À7.9, respectively; P ¼ NS).
The factors related to the UAE slope were sought using multiple regression analysis. The genotype of the A-6G polymorphism was the main factor, accounting for 17% of the variance. The influence of the A-6G genotype remained significant after including the type of treatment and the slopes for (Table 4) . Of the 35 subjects who initially were microalbuminurics, 24 became normoalbuminurics during the 3 years of antihypertensive treatment. Although the type of treatment did not differ among the genotypes of the A-6G polymorphism (subjects receiving ACEi were five out of the eight in the AA genotype, eight out of the 17 in the AG one and six out of the 10 with the GG one), there were significant differences in the normalization rates of microalbuminuria within the genotypes. The lowest reduction rates were observed within subjects who carried the allele A-6 (AA, four out of eight; AG, 10 out of 17; GG, 10 out of 10; Po0.04). The distribution of the A-6 allele frequency among the subjects who remained microalbuminuric was 0.68, in contrast with 0.37 among the subjects who normalized the microalbuminuria (relative risk 2.14, 95% CI 1.00-4.61; P ¼ 0.04).
Discussion
In a population of young adults with essential hypertension, never previously treated with antihypertensive drugs, the AA-6 genotype of the AGT gene seemed to influence the outcome of microalbuminuria. Despite a larger decrease in DBP among subjects carrying this genotype as compared to the other genotypes, a lower rate of patients with decreasing microalbuminuria and a higher UAE slope over time were observed in homozygotes for the A-6 allele. This blunted reduction in UAE was accompanied by an increase not only in fasting glucose levels but also in the slope of glucose over time.
Genetic analysis of complex traits and diseases, such as hypertension-induced end-organ damage, is difficult because of polygenic origins, genetic heterogeneity, variable penetrance, unknown modes of inheritance and the variable effects of environmental factors. [22] [23] The most common analytical approach is to look for associations in cross-sectional studies, and less commonly to analyse the outcomes of prospective studies. 7 Studies analysing data at large offer a more powerful tool than the crosssectional studies do. In the present study, we have studied the influence of the AGT polymorphism in the UAE of essential hypertensives by observing its impact on the outcome of microalbuminuria during antihypertensive treatment. This is a 3-year followup study, conducted in a homogeneous group of essential hypertensives, not previously treated with antihypertensive drugs. Our approach has permitted us to obtain information complementary to that of association studies about genetics on the development of microalbuminuria.
Among the several AGT gene polymorphisms, we selected the A-6G of the promoter region because recent studies of promoter activity and DNA-binding properties have suggested that the nucleotide substitution in the 5 0 upstream core promoter region of the human AGT gene affects the basal transcriptional rate of the gene. 13 The functional role of the M235T polymorphism alone or in conjunction with the A-6G, however, cannot be excluded. A rise or fall of AGT levels leads to a parallel change in the formation of angiotensin II, due to the plasma concentration being close to the Michaelis constant of the enzymatic reaction between AGT and rennin, 24 and it has implications for the pathogenesis of hypertension. We also analysed the M235T polymorphism at exon 2, the first of the polymorphisms associated with the development of hypertension.
Several studies have demonstrated that a reduction of BP values with antihypertensive drugs is accompanied by a decrease in microalbuminuria proportional to the reduction in BP. Both ACE inhibitors as well as antagonists of the angiotensin II AT1-receptor have additional beneficial effects on microalbuminuria, independent of BP reduction. 25 Individual responses, however, are quite variable. In the present study, antihypertensive treatment reduces UAE, and although the sample size was small, ACEi reduces UAE more than any other antihypertensive drug used. The changes in UAE, however, are not equally distributed among the genotypes of the A-6G polymorphism. In spite of the effect of ACEi in reducing UAE, the A-6G genotypes do not seem to modify the observed trends in UAE of the total study population. The fact that the presence of the AA-6 genotypes blunts the reduction in UAE, despite having the highest BP reductions, indicates 5, 6 In accordance with this, the present data seem to show that the patients with the AA-6 genotype are prone to develop a disturbance of the glucose metabolism as manifested by an increase of baseline glucose values. The role of the RAS in regulating insulinresistance has received attention recently. Angiotensin II increases peripheral resistance and contributes to the reduced muscular capillary blood flow present in hypertension. 26 Furthermore, overactivity of the RAS impairs insulin signalling and contributes to the insulin resistance observed in essential hypertension. 27 Whether or not the changes in the carbohydrate metabolism among the AA-6 genotype subjects can be explained by the highest AGT gene expression and the AGT plasma levels ascribed to this genotype needs to be explored in further studies. Although the present data, regarding whether the reduction in UAE is similar to the trend in subjects treated with ACEi and in those treated with other drugs, challenges the previous hypothesis of the potential role of the A-6G polymorphism in insulin resistance, an incomplete blockade of the angiotensin II generation by the ACEi might also explain the results.
In conclusion, this follow-up study offers us the opportunity to observe the impact of the A-6G polymorphism of the AGT gene on UAE over time in essential hypertensives. Subjects carrying the AA-6 genotype are more resistant to a reduction of microalbuminuria. Whether this can be attributed to a predisposition to glucose metabolic disturbance or not needs to be confirmed in further studies. If it can be a more specific approach in terms of preventing carbohydrate metabolism derangement, it might be recommended to reduce cardiovascular and renal risk in these subjects.
